Preview Newsletter
XARELTO Media Monitoring – Week of 7-1-16
-
Xarelto Lawsuit Plaintiffs Allege Lack Of Antidote For Several Years Put Patients At Risk
Jun 24, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces that case selection in the mass litigation against Xarelto began earlier this year. The bellwether action brings the more than 2,200 suits represented by multidistrict litigation (MDL) 2592 before Judge Eldon Fallon, presiding in the Eastern District of Louisiana, who will determine the nature of the allegations against the new-generation anticoagulant. -
Additional Xarelto Lawsuit Filings Expected As Litigation Moves Forward In MDL
Jun 24, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the selection of cases for the multidistrict litigation (MDL 2592) against Xarelto. The individual cases number over 2,000 and bring similar allegations against the new-generation anticoagulant and it's manufacturers—Bayer AG and Janssen Pharmaceuticals. Presiding over the MDL in the Eastern District of Louisiana is Judge Eldon Fallon. -
Xarelto Lawsuit Cases Continue To Draw Attention and Support
Jun 25, 2016 | TheProductLawyers.com
By Banville Law
June 25, 2016 – /PressAdvantage/ – TheProductLawyers.comreports on the recent developments in regards to the multitude of cases brought against the manufacturers of the anticoagulant drug, Xarelto. Lawsuits seeking damages from the manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) have surpassed 3,000 in number, and many allege similar harm as a result of taking the drug. -
Xarelto Lawsuit Cases In MDL Proceed Towards A Court Date
Jun 26, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the most recent actions in the litigation against the manufacturers of the new-generation anticoagulant, Xarelto. During the last months of 2015, the U.S. Judicial Panel on Multidistrict Litigation elected to combine the 2,800 cases alleging harm from the drug in order to streamline the legal process. They created multidistrict litigation (MDL) No. 2592, which will be presented in the Eastern District of Louisiana. Judge Eldon Fallon is overseeing the case. -
Xarelto Lawsuit Cases Consolidated Into MDL By JPML
Jun 27, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces the consolidation of cases against Janssen Pharmaceuticals and Bayer AG, which manufacture the anticoagulant, Xarelto. Numbering in excess of 2,800, the plaintiffs originally petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) in October of last year. They requested consolidation based on the similarity of claims and asked that the cases be tried in the Southern District of Illinois. However, the defendants’ lawyers disputed this location. They stated that New Jersey was a more logical venue since many of the manufacturers’ corporate offices are located there. -
Bellwether Selection Moves Xarelto Lawsuit Cases Closer To Court Dates
Jun 29, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Multidistrict Litigation (MDL) 2592. The U.S. Judicial Panel on Multidistrict Litigation (JPML) ordered the consolidation of more than 3,000 similar cases against Xarelto and its manufacturers late in 2015. Plaintiffs commonly allege that taking the anticoagulant placed them at a substantially increased risk of catastrophic bleeding events. The JPML decreed that all subsequent lawsuits brought before federal courts should be merged with the MDL. -
Ohio Couple Files Xarelto Lawsuit And Joins MDL
Jun 29, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com examines the details of a case recently filed by an Ohio couple against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson.) The lawsuit brings allegations of undue harm as a result of the wife's prescribed use of the anticoagulant, Xarelto, and seeks damages in excess of $150,000. -
As Xarelto Lawsuit Plaintiffs Prepare, Bellwether Trials Draw Nearer
Jun 30, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the progress of the multidistrict litigation (MDL) 2592 against Xarelto and its manufacturers, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson Corporation.) Late in 2015, the U.S. Judicial Panel on Multidistrict Litigation responded to the petition to combine nearly 3,000 individual suits with similar claims. -
Uncontrollable Bleeding Alleged In Xarelto Lawsuit Filings As MDL Progresses
Jun 24, 2016 | The Legal Examiner
By Laurence Banville
TheProductLawyers.com examines the combination of more than 2,000 lawsuits against Xarelto and its manufacturers—Janssen Pharmaceuticals and Bayer AG. Each of the cases contains similar allegations and has been merged into multidistrict litigation (MDL) 2592, to be tried collectively in the Eastern District of Louisiana. Presiding over the case is Judge Eldon Fallon. -
Xarelto Lawsuit Filed Against Makers of Drug
Jun 26, 2016 | TheRappaportLawFirm.com
By Rappaport Law
On Nov. 20, 2015, remaining family members of individuals who had taken Xarelto, and passed away in a serious bleeding event, filed a wrongful death lawsuit. Involving 10 plaintiffs, according to the Digital Journal, the Xarelto Lawsuit was filed in St. Clair County Circuit Court. (IL) -
Florida Woman Files Xarelto Lawsuit After Husband Dies
Jun 27, 2016 | Top Class Actions
By Kim Gale
A Florida woman has filed a Xarelto lawsuit after her husband died from severe internal bleeding after being on the medication for only five weeks. -
Xarelto Lawsuit Claims Receive Scholarly Support
Jun 30, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on the ongoing cases of many who filed lawsuits against Janssen Pharmaceuticals—a subsidiary of Johnson & Johnson—and Bayer AG. Their claims allege that they were exposed to a substantially increased risk of catastrophic bleeding events while taking the anticoagulant Xarelto. Several studies appear to lend credibility to these claims and have been thoroughly reviewed as a result.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Xarelto Lawsuit Plaintiffs Allege Lack Of Antidote For Several Years Put Patients At Risk
Jun 24, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces that case selection in the mass litigation against Xarelto began earlier this year. The bellwether action brings the more than 2,200 suits represented by multidistrict litigation (MDL) 2592 before Judge Eldon Fallon, presiding in the Eastern District of Louisiana, who will determine the nature of the allegations against the new-generation anticoagulant.
Initially hailed as a breakthrough in the treatment of blood clots and attendant complications, critics now call Xarelto the most dangerous blood thinner on the market today. In many ways, the anticoagulant stood above the more established treatment options in that it offered users more freedom from dietary restrictions and physician monitoring. The manufacturers, however, released it without an accompanying antidote, which means that even a minor injury could become life-threatening. Xarelto remained available to the public for several years without an antidote.
All other anticoagulant drugs in use possessed an antidote in the instance that complications with the drug arise. If a bleeding event occurs, the physician administering a traditional blood thinner can treat their patient with vitamin K. This reverses the drug's impact and permits the body to heal itself. While blood clots in the circulatory system can be fatal, inability to clot a wound or internal rupture can also be deadly.
Physicians treating patients on Xarelto had to consider surgery or other drastic, life-saving measures in the event of bleeding because the impact of the drug could not be counteracted. This means that clotting could not occur and a catastrophic bleeding episode could possibly result in death. Several plaintiffs allege that use of the drug placed them at an increased risk of serious harm or death.
While selection for the bellwether cases began earlier in 2016, information about the potential issues involved with Xarelto use is becoming more widespread. This may result in additional cases being brought against the manufacturers of the anticoagulant in the coming year, as those who claim to have suffered harm while on Xarelto seek damages.
http://www.digitaljournal.com/pr/2986070#ixzz4CsouIuNP
-
Additional Xarelto Lawsuit Filings Expected As Litigation Moves Forward In MDL
Jun 24, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the selection of cases for the multidistrict litigation (MDL 2592) against Xarelto. The individual cases number over 2,000 and bring similar allegations against the new-generation anticoagulant and it's manufacturers—Bayer AG and Janssen Pharmaceuticals. Presiding over the MDL in the Eastern District of Louisiana is Judge Eldon Fallon.
Even though it was originally hailed as a breakthrough in the treatment and prevention of blood clots and the attendant complications, such as strokes, critics of the drug have called it the most dangerous blood thinner on the market to date. It was released for use without an antidote, which, in the instance of complications, is essential.
Because other, more established anticoagulant drugs act differently from Xarelto—a fact that initially brought positive attention to the new-generation drug—doctors can easily treat a bleeding event. By treating a patient with the antidote of vitamin K, physicians reverse the blood-thinning action of traditional anticoagulants and allow the body to heal itself. While mobile clots within the circulatory system can be harmful or even fatal, the body must be able to close wounds, which it does by patching the breach with platelets. Blood thinners prevent this action, no matter where in the body it might occur. Without an antidote, even relatively minor bleeding events can quickly become catastrophic and potentially fatal.
For patients who were using Xarelto, doctors had to consider drastic or invasive procedures, such as surgery, in the event that they began to bleed. Several plaintiffs claim in their lawsuits that the manufacturers of Xarelto were negligent in allowing the drug to be approved, released, and aggressively marketed without such an antidote for so long.
Although selection for bellwether case took place earlier this year, the additional information these proceedings have brought to light will continue to spread. Individuals who may have suffered harm as a result of taking the anticoagulant are likely to seek damages as this case progresses.
http://www.digitaljournal.com/pr/2986178#ixzz4CsqVpni9
-
Xarelto Lawsuit Cases Continue To Draw Attention and Support
Jun 25, 2016 | TheProductLawyers.com
By Banville Law
June 25, 2016 – /PressAdvantage/ – TheProductLawyers.comreports on the recent developments in regards to the multitude of cases brought against the manufacturers of the anticoagulant drug, Xarelto. Lawsuits seeking damages from the manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) have surpassed 3,000 in number, and many allege similar harm as a result of taking the drug.
To the ends of expediting the process, the U.S. Judicial Panel on Multidistrict Litigation elected to merge 2,800 individual cases into the multidistrict litigation (MDL) case No. 2592. The combination lawsuit will be tried in the Eastern District of Louisiana. A similar agglomeration occurred in Pennsylvania, where 550 cases merged to form a mass tort program, completed by the Philadelphia Court of Common Pleas.
The rationale motivating these combinations lies in the similarity of stated grievances and the allegations brought against the drug manufacturers. Individuals claim that, because neither they nor their physicians were appropriately apprised of the possible elevated risk for the occurrence of sudden dangerous bleeding episodes associated with taking the drug, they were placed in danger of harm without due knowledge.
The FDA granted approval to the new-generation anticoagulant in 2011. It was originally intended for use by those suffering from pulmonary embolism or deep vein thrombosis and as a preventative measure for those recovering from hip or knee replacement surgery. Its approved uses were expanded shortly thereafter to treat individuals with atrial fibrillation, a heart condition that increases the risk for stroke.
While the cases have not yet gone to trial, plaintiffs are offered a measure of comfort. In the recent past, a similar case was made against the drug Pradaxa, which resulted in a multitude of lawsuits, which were settled out of court.
http://www.wdrb.com/story/32308668/xarelto-lawsuit-cases-continue-to-draw-attention-and-support
-
Xarelto Lawsuit Cases In MDL Proceed Towards A Court Date
Jun 26, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the most recent actions in the litigation against the manufacturers of the new-generation anticoagulant, Xarelto. During the last months of 2015, the U.S. Judicial Panel on Multidistrict Litigation elected to combine the 2,800 cases alleging harm from the drug in order to streamline the legal process. They created multidistrict litigation (MDL) No. 2592, which will be presented in the Eastern District of Louisiana. Judge Eldon Fallon is overseeing the case.
Expected to begin early in 2017 are four bellwether trials. Four cases will be selected for trial by jury in order to observe the reaction of jurors to evidence and testimony pertinent to the MDL. The outcomes of these trials will then be applied to future trials. Although the first two bellwether trials will be heard in the Eastern District of Louisiana on February 6th and March 13th, respectively, the third and fourth cases have been relocated to other districts. They will be brought before the court on April 24th and May 30th of 2017.
Initially embraced as a wonder drug, the new-generation anticoagulant has since fallen in the opinions of both medical circles and the public. Xarelto has been the focus of increasing litigation over the past few years, in which several major trends in allegations have emerged. Plaintiffs in MDL No. 2592 claim that use of the drug places them at an elevated risk of suffering severe bleeding episodes, and that the drug companies were negligent in their duty to inform both patients and physicians of this risk.
The Philadelphia Court of Common Pleas has also consolidated lawsuits to create a mass tort program of 550 cases leveling charges against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. In sum, the number of cases represented by these two combined groups stands to reach 4,000. Those involved in the litigation expect that as the date for the first bellwether trial in the MDL case nears, additional plaintiffs will come forward to join the group.
http://www.digitaljournal.com/pr/2986326#ixzz4CsrgK4il
-
Xarelto Lawsuit Cases Consolidated Into MDL By JPML
Jun 27, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces the consolidation of cases against Janssen Pharmaceuticals and Bayer AG, which manufacture the anticoagulant, Xarelto. Numbering in excess of 2,800, the plaintiffs originally petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) in October of last year. They requested consolidation based on the similarity of claims and asked that the cases be tried in the Southern District of Illinois. However, the defendants’ lawyers disputed this location. They stated that New Jersey was a more logical venue since many of the manufacturers’ corporate offices are located there.
After many weeks of deliberation, the JPML issued a statement on December 4, 2015. It was announced in this statement, "In our judgment, the considerable growth in the litigation over the past few months demonstrates that informal coordination is not practical." Consolidating the cases will conserve time, money, and public resources. It will also prevent acts of spurious discovery on the part of the defense and differing rulings issued by multiple judges.
The JPML also appointed a specially selected judge to preside over the cases in the neutral location of the Eastern District of Louisiana. They stated, "Judge Eldon E. Fallon, who presides over three potential tag-along actions, is an experienced transferee judge with the willingness and ability to manage this litigation efficiently. He is well-versed in multidistrict litigation and we are confident that he will steer this matter on a prudent course."
Following swiftly on the heels of this verdict, the consolidation occurred on December 12, 2015. While MDL 2592 has consolidated all federally-filed cases against Xarelto, other mass litigations are already taking shape. In Pennsylvania, a mass tort program comprising 550 individual lawsuits was consolidated by the Philadelphia Court of Common Pleas. Given this and other recent developments, plaintiffs are confident that individual claims against Xarelto will continue to appear as the lawsuits proceed to trial.
http://www.digitaljournal.com/pr/2987891#ixzz4CsrIociB
-
Bellwether Selection Moves Xarelto Lawsuit Cases Closer To Court Dates
Jun 29, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Multidistrict Litigation (MDL) 2592. The U.S. Judicial Panel on Multidistrict Litigation (JPML) ordered the consolidation of more than 3,000 similar cases against Xarelto and its manufacturers late in 2015. Plaintiffs commonly allege that taking the anticoagulant placed them at a substantially increased risk of catastrophic bleeding events. The JPML decreed that all subsequent lawsuits brought before federal courts should be merged with the MDL.
Based on plaintiff claims, the drug companies of Janssen Pharmaceuticals (a branch of Johnson & Johnson Corporation) and Bayer AG are named as defendants. In the interest of further expediting the process of justice, on December 17th, the presiding judge, Eldon Fallon, issued a court order for bellwether cases. This procedure entailed selecting 40 individual cases from among the MDL cases as an example pool. These bellwether cases will be considered representative of the larger overall pool of cases, and will be tried before a jury in order to determine the best way for both parties to move forward with litigation.
Both plaintiffs and defendants were instructed to select ten cases from the states of Mississippi, Louisiana, and eight other states that were the most trial-ready. The court drew twenty other cases from states that had the most claims against Xarelto, including Louisiana and Mississippi, and merged them with the lawsuits chosen by the two parties. These selections, completed by January 11th, will provide a range of examples for the selection of four bellwether cases later this year.
While MDL No. 2592 is moving closer to its first court date, plaintiffs are confident that additional lawsuits will continue to appear. As per the federal Judicial Panel's edict, those cases with similar allegations will be merged with the MDL in order to prevent squandering time, money, or resources of either party or the public. In the interest of all parties, the JPML also declared that the Eastern District of Louisiana will oversee the proceedings.
http://www.digitaljournal.com/pr/2990779#ixzz4DAOyXWpM
-
Ohio Couple Files Xarelto Lawsuit And Joins MDL
Jun 29, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com examines the details of a case recently filed by an Ohio couple against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson.) The lawsuit brings allegations of undue harm as a result of the wife's prescribed use of the anticoagulant, Xarelto, and seeks damages in excess of $150,000.
As purported by the plaintiffs, the woman included the drug as part of a preventative regimen, advised by her physician. However, after only two months into the treatment, she began experiencing severe difficulties. Court documents claim that she suffered an uncontrolled intestinal bleed, and could not heal the internal breach because she was using an anticoagulant medication.
As a result of the bleeding event, she also suffered from anemia and other complications that have impaired her ability to live a functional and satisfying life. The claim also indicates that she will require long-term treatment to remedy the difficulties associated with the trauma. Therefore, the couple has sued for damages to cover existing and future medical bills related to the event.
The FDA approved the new-generation anticoagulant in 2011. It's originally approved uses included treatment of patients with pulmonary embolism or deep vein thrombosis, as well as a postoperative clot prevention tactic for individuals recovering from hip or knee replacement surgeries. Soon afterward, Xarelto was also approved as a preventative measure for individuals with atrial fibrillation. The cardiac condition can place patients at an increased risk of stroke.
In response to the overwhelming number of cases with similar allegations against Xarelto, the U.S. Judicial Panel on Multidistrict Litigation (JPML) has complied with a request to combine the lawsuits. They ordered the formation of a multidistrict litigation (MDL 2592), which will be tried in the Eastern District of Louisiana under Judge Eldon Fallon. Additionally, the JPML dictated that all subsequent, federally-filed lawsuits with common claims against the drug—such as that filed by the Ohio couple—will be incorporated into the MDL. Plaintiffs expect to see increasing numbers of lawsuits as litigations proceed.
http://www.digitaljournal.com/pr/2990409#ixzz4DAPRFPhH
-
As Xarelto Lawsuit Plaintiffs Prepare, Bellwether Trials Draw Nearer
Jun 30, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the progress of the multidistrict litigation (MDL) 2592 against Xarelto and its manufacturers, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson Corporation.) Late in 2015, the U.S. Judicial Panel on Multidistrict Litigation responded to the petition to combine nearly 3,000 individual suits with similar claims.
In the interest of conserving resources, both public and private, the JPML agreed to proceed. As an additional measure to expedite the trial, they appointed Judge Eldon Fallon to preside over the mass litigation in the Eastern District of Louisiana. Any additional lawsuits with similar claims brought before federal courts are designated to be included in the existing MDL.
There are several allegations leveled at the massive drug manufacturers, many of which are held in common by the plaintiffs. Perhaps the most common is a claim that taking the anticoagulant placed individuals at a substantially increased risk of a catastrophic bleeding event. This is the occurrence of bleeding that cannot be stopped, except in some cases, with immediate and drastic medical intervention.
On December 17th, shortly after the JPML issued its decision, Judge Fallon instructed both parties to select ten cases from the lawsuits of the MDL. These cases must be among the readiest to proceed to trial, and drawn from the states with the most claims. The court then merged the cases with another twenty court-selected lawsuits drawn from Louisiana, Mississippi, and eight other states.
These, Judge Fallon explained, would form a trial pool from which four cases would then be drawn for bellwether proceedings. Commonly used as a measure to further expedite lengthy and complex court cases, bellwether trials allow both the plaintiffs and the defendants to present evidence before a jury panel. They can then observe the reactions, draw conclusions, and tailor their approach in subsequent case hearings.
As plaintiffs await the coming trials of MDL 2592, they are confident that subsequent lawsuits will continue to be joined into the MDL .
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.abc6.com/story/32341692/as-xarelto-lawsuit-plaintiffs-prepare-bellwether-trials-draw-nearer
-
Uncontrollable Bleeding Alleged In Xarelto Lawsuit Filings As MDL Progresses
Jun 24, 2016 | The Legal Examiner
By Laurence Banville
TheProductLawyers.com examines the combination of more than 2,000 lawsuits against Xarelto and its manufacturers—Janssen Pharmaceuticals and Bayer AG. Each of the cases contains similar allegations and has been merged into multidistrict litigation (MDL) 2592, to be tried collectively in the Eastern District of Louisiana. Presiding over the case is Judge Eldon Fallon.
Initial Approval And Release To Market
Although both the public and medical communities initially received it with acclaim, Xarelto is now considered by its many critics to be one of the most dangerous blood thinners on the market. When first released, it gained popularity because it offered users more freedoms than traditional anticoagulant medications. However, the drug was released to market without an available antidote. An antidote was not made available until several years later when a multitude of lawsuits had already been filed alleging that patients had suffered life-threatening bleeds or died as a result of being unable to counteract the drug.
Traditional Anticoagulants
With other, established and traditional anticoagulant drugs that are used today, an antidote exists in the use of vitamin K. Physicians treat patients who develop bleeding while on these medications with vitamin K, reversing the anticoagulant action and allowing the body to patch the breach with platelets.
What Happens When There Is No Antidote?
The lack of antidote meant that if someone with Xarelto in their system began to bleed, even from a seemingly minor injury, physicians may have been unable to clot their blood by countering the effects of Xarelto. Unchecked bleeding events can lead to damage of multiple bodily systems and even death. Doctors whose patients were taking the drug had to consider more extreme solutions. Surgery or other invasive and damaging actions may have proved necessary in order to save a life.
Lawsuits Continue To Grow In Number
Based on this body of understanding, the fact that the drug was approved and aggressively marketed to the visible enrichment of the manufacturers adds fuel to the plaintiffs’ claims. Plaintiffs involved in Xarelto multidistrict litigation also allege that the drug put them at an increased risk for dangerous, uncontrollable bleeding. Since the formation of the Xarelto MDL, lawsuit numbers have rapidly increased. While the selection of bellwether cases took place earlier this year, it is expected that those who may have suffered harm as a result of a bleeding event while on the drug will continue to seek redress.
http://newyorkcity.legalexaminer.com/fda-prescription-drugs/uncontrollable-bleeding-alleged-in-xarelto-lawsuit-filings-as-mdl-progresses/
-
Xarelto Lawsuit Filed Against Makers of Drug
Jun 26, 2016 | TheRappaportLawFirm.com
By Rappaport Law
Xarelto Lawsuit Filed Against Makers of Drug
A Xarelto Lawsuit has been filed against the makers of the drug, according to recent reports.
On Nov. 20, 2015, remaining family members of individuals who had taken Xarelto, and passed away in a serious bleeding event, filed a wrongful death lawsuit. Involving 10 plaintiffs, according to the Digital Journal, the Xarelto Lawsuit was filed in St. Clair County Circuit Court. (IL)
The Xarelto Lawsuit was filed against the makers of the drug, which includes Bayer and Janssen Pharmaceuticals.
“The (Xarelto) suit alleges that because of deceptive marketing using celebrities as spokespersons, the public was not sufficiently informed about the potentially dangerous side effects of taking Xarelto. It is alleged that despite the company’s research showing otherwise, the makers of the drug knowingly and fraudulently depicted it as a safe option for patients that had undergone knee and hip replacement procedures or as a treatment for a medical condition impacting the heart called atrial fibrillation,” writes the Digital Journal.
According to reports, the manufacturers of the prescription drug Xarelto were warned in June 2013, by the U.S. Food and Drug Administration (FDA), that their marketing of the drug was misleading. They were warned to stop such advertising practices. However, no changes were made on behalf of the makers of Xarelto.
Xarelto Lawsuit Filed Against Makers of Drug
Those who have filed a lawsuit against the makers of Xarelto are reportedly asking for $50,000 in damages, per each deceased family member; in addition to attorney’s fees and other legal costs.
“The plaintiffs, in this case, are requesting a minimum payment of $50,000 for each deceased family member with the purpose of covering medical bills, funeral expenses, legal fees and other such costs to compensate for the pain and suffering endured by those family members left behind,: writes the Digital Journal. “There have been nine counts of misconduct ranging from wrongful death to fraud.”
-
Florida Woman Files Xarelto Lawsuit After Husband Dies
Jun 27, 2016 | Top Class Actions
By Kim Gale
A Florida woman has filed a Xarelto lawsuit after her husband died from severe internal bleeding after being on the medication for only five weeks.
Plaintiff Lourdes P. claims her late husband, Jorge P.’s wrongful death occurred after he was prescribed the anticoagulant Xarelto on Sept. 9, 2014 to treat atrial fibrillation.
In October 2014, Jorge was hospitalized with severe internal bleeding. Among his serious issues were kidney injury with hemorrhagic shock, which means his cells were not receiving enough oxygen.
He was bleeding into his abdominal wall and experienced respiratory failure as well, the Xarelto lawsuit states.
His internal bleeding was uncontrollable, and his condition deteriorated. Jorge died on Oct. 14, 2014 at the age of 74, allegedly from his Xarelto-induced injuries, according to Lourdes’ Xarelto lawsuit.
Unfortunately, Jorge is not the first person to allegedly suffer horrific injuries and die as a result of Xarelto side effects.
Hundreds of Xarelto lawsuits for injuries and wrongful death have been filed against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals regarding anticoagulant Xarelto.
Accused of falsifying and skewing test results to make Xarelto appear more effective than other, older anticoagulants, the manufacturers are also in the line of fire for heavily marketing the drug using the unsubstantiated data.
Commonly referred to as blood thinners, anticoagulants prevent blood clots and to prevent strokes. Unfortunately, blood thinners can also cause uncontrollable internal bleeding that can lead to death.
Xarelto has been marketed as the leader of a new class of anticoagulants that don’t need blood monitoring like the older blood thinners, such as warfarin, do.
Xarelto has been marketed as a “one size fits all” medication.
Older anticoagulants such as warfarin require blood monitoring to control medication levels. While that can be a hassle for patients, at least they know that warfarin has an antidote that can reverse its anti-clotting effects in the event of a surgery or injury to the patient taking the medication.
Xarelto Side Effects
Of Xarelto side effects, the most common is bleeding, but it can range from minor bleeding all the way to being fatal.
The main concern is if someone is bleeding out, there is no antidote for Xarelto. As of now, there are no instructions for physicians to control bleeding caused by Xarelto’s blood-thinning properties.
With no way to stop the bleeding, the Xarelto lawsuits for wrongful death are justifiable.
According to the FDA’s Adverse Reporting System, additional Xarelto side effects can include:thrombosis (blood clots)decreased hemoglobin (a substance that carries oxygen in red blood cells)cerebrovascular accidents (an event that leads to a stroke, such as a cerebral hemorrhage)hematoma (a semisolid mass in the blood)peripheral edema (swelling of the lower limbs)
Filing a Xarelto Lawsuit
If you or someone you know has taken the medication and suffered Xarelto side effects, you could be eligible for compensation for your loss of wages, medical expenses, pain and suffering and other damages by filing a Xarelto lawsuit.
The Xarelto Lawsuit is Case No. 1:16-cv-21428 in U.S. District Court Southern District of Florida Miami Division.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/338620-florida-woman-files-xarelto-lawsuit-husband-dies/
-
Xarelto Lawsuit Claims Receive Scholarly Support
Jun 30, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on the ongoing cases of many who filed lawsuits against Janssen Pharmaceuticals—a subsidiary of Johnson & Johnson—and Bayer AG. Their claims allege that they were exposed to a substantially increased risk of catastrophic bleeding events while taking the anticoagulant Xarelto. Several studies appear to lend credibility to these claims and have been thoroughly reviewed as a result.
Increased Risk Of Vitreous Hemorrhages
Drs. John C. Hwang and Judy Hun observed patients from their practice who were currently participating in a long-term blood thinner regimen and ranged in age from 70 to 89. While they were originally taking more traditional medications, they switched to Xarelto after its FDA approval in 2011. According to empirical observation, these patients showed a marked increase in incidents of vitreous hemorrhages or eye-bleeding that appeared to coincide with their change in medication.
The doctors noted that the bleeding events were most likely to occur in those who had an established history of blood thinner use, such as warfarin, and switched to the new-generation anticoagulant. Hwang and Hun published their complete findings in the June 2015 issue of JAMA Ophthalmology, and noted, “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.”
Increased Risk Of Internal Bleeds
Another landmark study was published in the April 2015 issue of the British Medical Journal (BMJ) that indicated as high as a two-fold increase in the risk for stomach bleeds by patients taking Xarelto in lieu of warfarin. For the purposes of the study, investigators screened nearly 46,000 complete medical histories. It was noted that the bleeding events were most common in those who had been taking warfarin, but weaned off the drug in favor of the promising new treatment option presented by Xarelto.
Consolidation Of Lawsuits
In the United States, more than 2,800 individual cases against Xarelto and its manufacturers have been consolidated to form the multidistrict litigation (MDL) No. 2592. The common allegations of the plaintiffs in these cases include a substantially increased risk of catastrophic bleeding events, injury, and even death. Judge Eldon Fallon has been appointed to oversee the MDL proceedings in the Eastern District Court of Louisiana.
http://newyorkcity.legalexaminer.com/fda-prescription-drugs/xarelto-lawsuit-claims-receive-scholarly-support/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested